Overview and Outlook

Fiscal 2021

  • Group sales rise by 12.3% to € 19.7 billion; EBITDA pre up 17.3% to € 6.1 billion; EBITDA pre margin increases to 31.0%
  • Greater investments in high-growth businesses; net financial debt significantly lower
  • Earnings per share pre of € 8.72; proposed dividend rises by € 0.45 to all-time high of € 1.85

Forecast for 2022

  • Strong organic growth of net sales and EBITDA pre expected
  • All business sectors are forecast to contribute to the positive development; Life Science will remain the strongest growth engine of the Group

Despite a difficult environment, we have stayed a reliable partner for patients, scientists and our customers – and were hence able to achieve a record result.

Belén Garijo

Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

Annual Reports Archive

Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more

Related News

View All News
  1. Press Releases

    Fiscal 2021: Group Delivers Record Growth and Higher Profitability

    Merck KGaA, Darmstadt, Germany delivered record growth in fiscal 2021. In the course of the year, the company had already raised its business forecast three times.


Upcoming Events

View All Events

Andreas Cezanne

Financial Communications

Constantin Fest

Head of Investor Relations

+49 6151 72-5271

+49 6151 72 91-5271

Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.

Check Share Price